Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports

• Asıl Yazarlar: Zoe Apalla (Yazar), Marc Perrussel (Yazar), Efstathios Rallis (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BioExcel Publishing Ltd, 2022-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.
• Notes: 10.7573/dic.2022-4-3; 1740-4398
• Keywords: aerosol foam; betamethasone dipropionate; calcipotriol; psoriasis; Therapeutics. Pharmacology; RM1-950
• Source: Drugs in Context, Vol 11, Pp 1-7 (2022)

Psoriasis is a chronic inflammatory disease affecting about 100 million people worldwide. Around 80% of patients can be treated with topical agents, most commonly corticosteroids and vitamin D analogues. A topical foam formulation of calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD foam; Enstilar®) is approved for the daily treatment of psoriasis for up to 4 weeks and twice-weekly thereafter as maintenance treatment (after initial 4-week treatment success). Long-term proactive maintenance with Cal/BD foam for plaque psoriasis has been shown to prolong the time to first relapse, reduce the number of relapses and increase days in remission in the PSO-LONG trial. Four case studies of proactive management with Cal/BD foam for the treatment of plaque psoriasis for up to 12 months from initial presentation are described. These case studies provide real-world evidence on the long-term effectiveness of proactive management with Cal/BD foam as well as the improvement and maintenance of health-related quality of life. Cal/BD foam was well tolerated.